Human Molecular Genetics Advance Access published online on August 22, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi319
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Richard B. Simches Research Center, 185 Cambridge Street, Boston MA 02114
* To whom correspondence should be addressed. The expanded HD CAG repeat that causes Huntington's disease (HD) encodes a polyglutamine tract in huntingtin that first targets the death of medium spiny striatal neurons. Mitochondrial energetics, related to N-methyl-D-aspartate (NMDA) Ca2+-signaling, has long been implicated in this neuronal specificity, implying an integral role for huntingtin in mitochondrial energy metabolism. As a genetic test of this hypothesis, we have looked for a relationship between the length of the HD CAG repeat, expressed in endogenous huntingtin, and mitochondrial ATP production. In STHdhQ111 knock-in striatal cells, a juvenile onset HD CAG repeat was associated with low mitochondrial ATP and decreased mitochondrial ADP-uptake. This metabolic inhibition was associated with enhanced Ca2+-influx through NMDA receptors that, when blocked, resulted in increased cellular [ATP/ADP]. We then evaluated [ATP/ADP] in forty human lymphoblastoid cell lines, bearing non-HD CAG lengths (9-34 units) or HD-causing alleles (35-70 units). This analysis revealed an inverse association with the longer of the two allelic HD CAG repeats in both the non-HD and the HD range. Thus, the polyglutamine tract in huntingtin appears to regulate mitochondrial ADP-phosphorylation in a Ca2+-dependent process that fulfills the genetic criteria for the HD trigger of pathogenesis, and it thereby determines a fundamental biological parameter - cellular energy status, that may contribute to the exquisite vulnerability of striatal neurons in HD. Moreover, the evidence that this polymorphism can determine energy status in the non-HD range suggests that it be tested as a potential physiological modifier in both health and disease.
Received July 23, 2005
Revised August 16, 2005
Accepted August 16, 2005
Article
The HD CAG Repeat Implicates a Dominant Property of Huntingtin in Mitochondrial Energy Metabolism
2 Department of Psychiatry, University of Alabama at Birmingham, Birmingham, AL 35294
3 Department of Neurology, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts, MA 02118
Marcy E. MacDonald, E-mail: macdonam{at}helix.mgh.harvard.edu
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. A. Aziz, C. K. Jurgens, G. B. Landwehrmeyer, EHDN Registry Study Group, W.M.C. van Roon-Mom, G. J.B. van Ommen, T. Stijnen, and R. A.C. Roos Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease Neurology, October 20, 2009; 73(16): 1280 - 1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, et al. Impaired PGC-1{alpha} function in muscle in Huntington's disease Hum. Mol. Genet., August 15, 2009; 18(16): 3048 - 3065. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, P. J. Lim, M. Karbowski, and M. J. Monteiro Effects of overexpression of Huntingtin proteins on mitochondrial integrity Hum. Mol. Genet., February 15, 2009; 18(4): 737 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ranganathan, G. G. Harmison, K. Meyertholen, M. Pennuto, B. G. Burnett, and K. H. Fischbeck Mitochondrial abnormalities in spinal and bulbar muscular atrophy Hum. Mol. Genet., January 1, 2009; 18(1): 27 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Aziz, J.M.M. van der Burg, G. B. Landwehrmeyer, P. Brundin, T. Stijnen, EHDI Study Group, and R. A.C. Roos Weight loss in Huntington disease increases with higher CAG repeat number Neurology, November 4, 2008; 71(19): 1506 - 1513. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Paoletti, I. Vila, M. Rife, J. M. Lizcano, J. Alberch, and S. Gines Dopaminergic and Glutamatergic Signaling Crosstalk in Huntington's Disease Neurodegeneration: The Role of p25/Cyclin-Dependent Kinase 5 J. Neurosci., October 1, 2008; 28(40): 10090 - 10101. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, C.-E. Wang, A. Orr, S. Tydlacka, S.-H. Li, and X.-J. Li Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice J. Cell Biol., March 24, 2008; 180(6): 1177 - 1189. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lim, L. Fedrizzi, M. Tartari, C. Zuccato, E. Cattaneo, M. Brini, and E. Carafoli Calcium Homeostasis and Mitochondrial Dysfunction in Striatal Neurons of Huntington Disease J. Biol. Chem., February 29, 2008; 283(9): 5780 - 5789. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fukui and C. T. Moraes Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates Hum. Mol. Genet., April 1, 2007; 16(7): 783 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rockabrand, N. Slepko, A. Pantalone, V. N. Nukala, A. Kazantsev, J. L. Marsh, P. G. Sullivan, J. S. Steffan, S. L. Sensi, and L. M. Thompson The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis Hum. Mol. Genet., January 1, 2007; 16(1): 61 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. A. Oliveira, S. Chen, S. Almeida, R. Riley, J. Goncalves, C. R. Oliveira, M. R. Hayden, D. G. Nicholls, L. M. Ellerby, and A. C. Rego Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors J. Neurosci., October 25, 2006; 26(43): 11174 - 11186. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Solans, A. Zambrano, M. Rodriguez, and A. Barrientos Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III Hum. Mol. Genet., October 15, 2006; 15(20): 3063 - 3081. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. A. Brusilow Is Huntington's a Glutamine Storage Disease? Neuroscientist, August 1, 2006; 12(4): 300 - 304. [Abstract] [PDF] |
||||
![]() |
E. B.D. Clabough and S. O. Zeitlin Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro Hum. Mol. Genet., February 15, 2006; 15(4): 607 - 623. [Abstract] [Full Text] [PDF] |
||||





